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percorrida no teste de caminhada  de seis minutos em pacientes com 
câncer de pulmão avançado submetidos à quimioterapia
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Abstract
Objective: To evaluate the effect of chemotherapy on the physical condition of patients with advanced lung 
cancer. Methods: We evaluated 50 patients with non-small cell lung cancer (in stages IIIB and IV) and Eastern 
Cooperative Oncology Group (ECOG) performance status scale scores between zero and two. All patients underwent 
chemotherapy using paclitaxel and platinum derivatives and were evaluated at three time points (prechemotherapy, 
postchemotherapy and six months after starting the treatment), at which the ECOG scale, the body mass index (BMI) 
and the six-minute walk distance (6MWD) were assessed. Results: Of the 50 patients included in the study, 14 died, 
5 were excluded due to the worsening of their performance status, and 31 completed the six-month follow-up. 
There was no statistically significant difference between the time points of assessment for BMI (prechemotherapy 
vs. postchemotherapy, p = 1.00; and prechemotherapy vs. six months later, p = 0.218) or for 6MWD. Performance 
status improved, and this was especially due to the increase in the number of asymptomatic patients after the 
six-month follow-up (p = 0.031). Conclusions: Chemotherapy had a beneficial effect on the performance status of 
the patients. No significant changes in BMI or 6MWD were found during the study period, which might suggest 
the maintenance of the physical condition of the patients.
Keywords: Drug therapy; Lung neoplasms; Exercise tolerance.
Resumo
Objetivo: Avaliar o efeito da quimioterapia sobre a condição física de pacientes com câncer de pulmão avançado. 
Métodos: Foram avaliados 50 pacientes com câncer de pulmão não pequenas células nos estágios IIIB e IV e com 
status de performance segundo a escala do Eastern Cooperative Oncology Group (ECOG) entre zero e dois. Todos 
receberam quimioterapia com as drogas paclitaxel e derivados da platina e foram avaliados em três momentos 
(pré-quimioterapia, pós-quimioterapia e seis meses após o início do tratamento), nos quais a escala ECOG, o 
índice de massa corpórea (IMC) e a Distância percorrida no Teste de Caminhada de Seis minutos (DTC6) foram 
avaliados. Resultados: Dos 50 pacientes incluídos, 14 foram a óbito, 5 foram excluídos do estudo por apresentar 
piora do status de performance, e 31 concluíram o seguimento de seis meses. Não houve diferença estatisticamente 
significativa para o IMC (p = 1,00, pré-quimioterapia vs. pós-quimioterapia; e p = 0,218, pré-quimioterapia vs. seis 
meses após) ou para a DTC6 entre os momentos de avaliação. O status de performance melhorou, principalmente 
com o aumento do número de pacientes assintomáticos após seis meses de acompanhamento (p = 0,031). 
Conclusões: O uso de quimioterapia teve um efeito benéfico no status de performance dos pacientes. Não houve 
alterações no IMC ou na DTC6 durante o período do estudo, o que pode sugerir a manutenção da condição física 
dos pacientes.
Descritores: Quimioterapia; Neoplasias pulmonares; Tolerância ao exercício.
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2. All of the patients received clinical treatment 
with paclitaxel and platinum derivatives. The 
drugs were administered in a single dose, every 
three weeks, for four cycles. In each cycle 
of chemotherapy, patients < 70 years of age 
received paclitaxel (175 mg/m2) and cisplatin 
(80 mg/m2), whereas those ≥ 70 years of age 
received paclitaxel (200 mg/m2) and carboplatin 
(area under the curve/5 = 300-600 mg/m2).
The initial exclusion criteria were as follows: 
having previously undergone lung surgery; and 
presenting with brain metastasis. During the 
study period, patients who presented with an 
ECOG PS score > 2 were excluded, in accordance 
with the treatment protocol of our facility, where 
chemotherapy is not given to such patients.(7) 
Therefore, the only exclusion criterion adopted 
during the follow-up visits was presenting with 
an elevated ECOG PS scale score (> 2).
All of the patients gave written informed 
consent. The study was approved by the 
local research ethics committee (ruling no. 
209/2006).
The patients were selected during medical 
visits to the Lung Cancer Outpatient Clinic of 
the State University at Campinas Hospital das 
Clínicas, located in the city of Campinas, Brazil. 
After the inclusion criteria had been applied, 
the patients were evaluated and data were 
collected.
The evaluations and data collection were 
carried out at three time points: prechemotherapy; 
postchemotherapy (two weeks after the last 
cycle of chemotherapy); and six months after 
the start of treatment. The evaluation consisted 
of collecting personal data, determining PS, 
evaluating BMI, and administering the 6MWT.
In order to determine the PS, we used 
the ECOG scale, which measures the overall 
functional performance of patients, the score 
on which is also an important therapeutic 
parameter. Patients are classified by score, 
which ranges from 0 to 4: 0 = asymptomatic; 
1 = presenting with disease symptoms but able 
to perform activities normally; 2 = symptomatic 
and often requiring outpatient treatment; 
3 = bedridden for more than 50% of the time; 
and 4 = completely bedridden.(12)
The BMI was calculated as the weight 
in kilograms divided by the square of the 
height in meters (kg/m2).(13) The patients were 
divided into three groups: underweight (BMI < 
Introduction
Lung cancer is a serious public health 
problem. It is currently the leading cause of 
cancer-related mortality, accounting for more 
than one million deaths worldwide.(1) It was 
estimated that, in 2008, there were 215,000 new 
cases of lung cancer, as well as 161,500 deaths 
from the disease, in the United States.(2) Estimates 
for Brazil indicate that 27,000 individuals 
(18,000 males and 9,000 females) had lung 
cancer in 2008 and 2009.(3) The comparison 
between the smoking populations in the two 
countries indicates that the incidence of lung 
cancer in Brazil is underestimated.
Although there have been advances in 
clinical research into the treatment of cancer, 
the mortality rate from lung cancer has not 
decreased significantly in the last three decades, 
principally because there are no methods for 
establishing an early diagnosis of this type of 
neoplasia. Because the vast majority of cases are 
diagnosed at advanced stages,(4) principally in 
Brazil. Although chemotherapy and radiotherapy 
are widely used, the role of these types of 
treatment in increasing survival and principally 
in improving quality of life is still subjective.(5,6)
In patients with advanced lung cancer, 
chemotherapy has been shown to have 
advantages over palliative treatment.(7) However, 
these patients experience symptoms and side 
effects, such as nausea, vomiting, infection, 
loss of appetite, and fatigue, which have been 
associated with reduced exercise capacity, 
inactivity, and impaired quality of life.(8-11)
The objective of the present study was 
to analyze the effect of chemotherapy on the 
physical condition of patients with advanced 
non-small cell lung cancer (NSCLC) by 
monitoring the evolution of the performance 
status (PS), as well as by evaluating body mass 
index (BMI) and assessing functional capacity 
with the six-minute walk test (6MWT).
Methods
This was a nonrandomized longitudinal 
clinical trial that evaluated the impact of 
chemotherapy on patients with lung cancer. 
Between May of 2006 and July of 2008, we 
evaluated 50 adult patients with NSCLC (stage 
IIIB or IV) and Eastern Cooperative Oncology 
Group (ECOG) PS scale scores between 0 and 
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As can be seen in Table 2, the baseline 
(prechemotherapy) ECOG scale results for the 
50 patients evaluated were as follows: a score 
of 0 (asymptomatic) in 4 (8%); a score of 
1 (symptomatic) in 33 (66%); and a score of 
2 (symptomatic and requiring treatment) in 
13 (26%). 
The postchemotherapy ECOG scale 
sco res revealed an increase in the number of 
asymptomatic patients. Of the 38 patients 
evaluated, 15 (39.5%) had a score of 0, 
22 (57.9%) had a score of 1, and only 1 (2.6%) 
had a score of 2. At six months after the start 
of treatment, the distribution of the ECOG 
scale scores was similar to that observed for the 
postchemotherapy time point (Table 2).
Table 3 shows the comparison between the 
initial PS and the final PS. Of the 31 patients 
who completed the six months of follow-up, 
4 (12.9%) presented worsening of the PS, the 
ECOG scale score increasing from 1 to 2 in 
3 patients and from 0 to 1 in 1. In addition, 
13 (41.9%) of the 31 patients maintained their 
prechemotherapy PS (ECOG scale score: 0 in 
2 patients; and 1 in 11 patients), whereas the PS 
improved in 18 (58.1%), the ECOG scale score 
decreasing from 1 to 0 in 14 (45.2%) and from 
2 to 1 in 4 (12.9%).
20 kg/m2); normal-weight (BMI ranging from 
20 to 25 kg/m2); and overweight (BMI ≥ 
25 kg/m2).
The 6MWT evaluates the maximum distance 
that the patients are able to walk in six minutes. 
The 6MWT was performed in a 30-m corridor, 
with clear guide marks on the floor. During the 
procedure, the patients were instructed, through 
the use of standardized verbal encouragement 
once a minute, to walk at their fastest pace. 
Before and after the test, we recorded the 
following variables: arterial pressure; HR; RR; 
SpO2; and degree of dyspnea, as determined 
by the Borg scale. The distance covered was 
quantified in meters. The criteria for interrupting 
the test were in accordance with the guidelines 
of the American Thoracic Society.(14)
The statistical analyses were performed 
using the program Statistical Package for 
the Social Sciences, version 15.0 (SPSS Inc., 
Chicago, IL, USA). We determined the mean, 
standard deviation, and quartiles of the 
quantitative variables. In order to compare the 
prechemotherapy and postchemotherapy time 
points, we used the Wilcoxon test. In order to 
compare the three time points (prechemotherapy, 
postchemotherapy, and six months after the 
start of treatment), we used the Friedman test. 
In order to evaluate changes in the distribution 
of the patients among the weight groups at the 
different time points, we determined bilateral 
probability using binomial distribution.(15,16)
Results
The present study was conducted over a 
period of 25 months. The initial study sample 
comprised 50 patients. Of those, 18 (36%) were 
female and 32 (64%) were male. Patient ages 
ranged from 41 to 79 years (mean, 61.64 ± 
9.33 years). A total of 31 patients completed the 
six-month follow-up.
Table 1 shows the baseline (prechemotherapy) 
analysis of the descriptive variables gender, age, 
disease stage, and smoking status.
Of the 50 patients evaluated, 38 completed 
the second evaluation (approximately 100 days 
after the start of treatment), 8 died, and 
4 presented worsening of the PS. By the end of 
the follow-up period, an additional 7 patients 
had been excluded: 6 had died; and 1 had 
presented worsening of the PS.
Table 1 - Characteristics of the study sample at the 
initial evaluation (n = 50).
Variable n (%)
Gender
 Female 18 (36)
 Male 32 (64)
Age bracket, years
 40-49 6 (12)
 50-59 12 (24)
 60-69 21 (42)
 ≥ 70 11 (22)
Stage
 IIIB 35 (70)
 IV 15 (30)
Performance statusa
 0 4 (8)
 1 33 (66)
 2 13 (26)
Smoker
 Yes 42 (84)
 No 8 (16)
aDetermined by the Eastern Cooperative Oncology Group 
Performance Status scale.
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9 (29%) were in the overweight group. It should 
be pointed out that, at six months after the 
start of treatment, 1 patient who was initially 
in the underweight group migrated to the 
normal-weight group and 4 patients who were 
initially in the normal-weight group migrated to 
the underweight group (p = 0.218; two-tailed 
binomial distribution).
The mean six-minute walk distance (6MWD) 
at the three time points (prechemotherapy, 
postchemotherapy, and six months after the 
start of treatment) was 431.5 ± 75.9 m (range, 
280-585 m), 437 ± 79.6 m (range, 180-550 m), 
and 431.5 ± 74.1 m (range, 280-585 m), 
respectively. One of the patients declined to 
perform the 6MWT at the final evaluation. 
The differences in mean 6MWD between the 
time points were not statistically significant 
(p = 0.781; Table 5).
Discussion
The combination of palliative treatment and 
chemotherapy, when compared with palliative 
treatment in isolation, has been shown to be 
effective in increasing the survival of patients 
with advanced lung cancer.(17) For patients with 
stage IIIB or IV NSCLC, chemotherapy regimens 
based on platinum derivatives have been shown 
to be beneficial in terms of survival and quality 
of life.(18,19) However, the treatment can have 
side effects and can impede the performance of 
activities of daily living.(11,20,21)
The present study monitored a group 
of patients with advanced NSCLC, with 
the objective of observing the evolution of 
aspects related to physical performance during 
chemotherapy and the effects of chemotherapy 
at six months after the start of treatment. We 
used simple instruments of measurement that 
can be easily employed in routine outpatient 
practice, instruments that can aid professionals 
in collecting information and identifying the 
consequences of the treatment.
The results of the present study showed that 
a large number of patients died, which reduced 
the sample size over the follow-up period. 
In fact, this was expected, since only patients 
with advanced lung cancer were included in 
the present study. Unfortunately, 75% of the 
patients who present to our pulmonology-
oncology facility have stage IIIB or IV lung 
cancer. In the study sample, 30% of the patients 
Table 4 shows that the mean BMI was 
23.4 ± 5.0 (range, 14.8-39.4 kg/m2) at the 
prechemotherapy time point, 23.2 ± 4.8 kg/m2 
(range, 15.5-38.0 kg/m2) at the postche mo-
therapy time point, and 23.9 ± 5.7 kg/m2 
(14.4-41.2 kg/m2) at six months after the start of 
treat ment. Of the 38 patients who completed the 
first two phases of the study, 10 (26.3%) had been 
classified as underweight at baseline, whereas 
14 (36.8%) had been classified as normal-weight 
and 14 (36.8%) had been classified as overweight. 
At the postchemotherapy time point, these 
proportions were, respectively, 10 (26.3%), 
18 (47.4%), and 10 (26.3%), respectively. 
For the evaluation of the impairment of the 
nutritional status, we compared the proportion 
of patients in the underweight group with the 
proportion of patients in the remaining groups. 
The proportion of patients in the underweight 
group was the same at the prechemotherapy 
and postchemotherapy time points (p = 1.000; 
two-tailed binomial distribution).
At six months after the start of treatment, 
9 patients (29%) were in the underweight group, 
13 (42%) were in the normal-weight group, and 
Table 2 - Evaluation of the Eastern Cooperative 
Oncology Group Performance Status scale scores of 
patients at the three evaluation time points.
ECOG 
scale 
score
Preche-
motherapy
Postche -
motherapy
Six months 
after the start 
of treatment
n (%) n (%) n (%)
0 4 (8.0) 15 (39.5) 12 (38.7)
1 33 (66.0) 22 (57.9) 16 (51.6)
2 13 (26.0) 1 (2.6) 3 (9.7)
Total 50 (100) 38 (100) 31(100)
ECOG: Eastern Cooperative Oncology Group.
Table 3 - Comparison between initial and final 
Eastern Cooperative Oncology Group Performance 
Status scale scores.
Initial 
ECOG 
scale 
score
Final ECOG scale scorea
0 1 2 Total
0 2 (66.7) 1 (33.3) 3 (100.0)
1 10 (41.7)* 11 (45.8) 3 (12.5) 24 (100.0)
2 4 (100.0)* 4 (100.0)
Total 12 (38.7) 16(51.6) 3 (9.7) 31 (100.0)
ECOG: Eastern Cooperative Oncology Group. aData 
expressed as n (%). *p = 0.031; McNemar’s test.
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this was especially due to the increase in the 
number of asymptomatic patients from baseline 
to six months after the start of treatment (4 vs. 
12), a finding that is in agreement with those of 
other studies.(7,19)
Weight loss is a common symptom in 
patients with lung cancer; however, the etiology 
of such weight loss has yet to be fully unders-
tood.(26) In the present study, for the evaluation 
of nutritional impairment, we considered the 
proportion of patients in each weight group at 
the three evaluation time points. The proportion 
of patients included in the underweight group 
was equal at the three evaluation time points. 
There were no significant differences among the 
three nutritional status groups at any of the three 
evaluations, which was evidence that there was 
no nutritional impairment after chemotherapy 
or at six months after the start of treatment 
(Table 4).
The 6MWT is used to evaluate submaximal 
exercise capacity and reproduce the effort put 
forth during routine activities. The 6MWT 
evaluates the overall and integrated responses of 
all systems involved in the exercise. However, it 
does not provide specific information regarding 
the mechanism of exercise limitation. The 6MWT 
is a simple, easily applicable, validated test that 
has been widely used in patients with respiratory 
and heart diseases.(14)
Although lung cancer is among the 
most common malignancies, the impact of 
chemotherapy on the exercise capacity of patients 
presented with distant metastasis. New strategies 
should be developed in order to allow earlier 
diagnosis, thus increasing the chances of patient 
survival.(22-24)
Determination of the PS is of great 
importance to the prognosis of cancer patients, 
and presenting with a PS within a given range 
has often been used as an inclusion criterion 
in clinical trials.(25) The patients included in 
the present study presented with preserved 
functional capacity, as evidenced by their ECOG 
scale scores, which ranged from 0 to 2. This 
criterion was chosen because adverse effects are 
more common in patients with an ECOG scale 
score > 2,(18) and the inclusion of such patients 
might have interfered with the monitoring of 
the clinical evolution and with the subsequent 
analysis of the effects of the treatment.
Of the 50 patients with advanced lung cancer 
who received chemotherapy, 14 (28%) showed 
improvement in the PS, 13 (26%) remained 
stable, and 23 (46%) showed worsening of 
the PS or died before or after the six-month 
follow-up period. It is of note that 54% of the 
patients investigated in the present study showed 
improvement in the PS or remained stable at the 
end of the six-month follow-up, which suggests 
that chemotherapy is beneficial for patients with 
advanced lung cancer.
As can be seen in Table 3, the analysis of 
the 31 patients who completed the six-month 
follow-up showed that the use of chemotherapy 
was clearly beneficial for the PS (p = 0.031), and 
Table 4 - Nutritional status of patients at the three evaluation time points.*
Group Prechemotherapy Postchemotherapy Six months after the  
start of treatment
Underweight, n (%) 10 (26.3) 10 (26.3) 9 (29.0)
Normal-weight, n (%) 14 (36.8) 18 (47.4) 13 (42.0)
Overweight, n (%) 14 (36.8) 10 (26.3) 9 (29.0)
Total, n (%) 38 (100.0)a 38 (100.0) 31 (100.0)
*p = 1.00 (prechemotherapy vs. postchemotherapy); p = 0.218 (prechemotherapy vs. six months after the start of treatment); 
two-tailed binomial distribution. bPatients who did not complete at least two of the three phases of the study were 
excluded from this analysis.
Table 5 - Six-minute walk distance at the three evaluation time points.
Time point Patients, 
n
Six-minute walk distance, m
Mean ± SD Median Range Interquartile range
Prechemotherapy 30 431.3 ± 75.9 435.0 280.0-585.0 365.0-490.0
Postchemotherapy 30 433.2 ± 86.7 437.5 180.0-550.0 380.0-505.0
Six months after the start of treatment 30 424.4 ± 72.5 420.0 270.0-572.0 380.0-465.0
p = 0.781; the Friedman test.
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with NSCLC has yet to be fully understood. In 
the present study, the 6MWT results allowed 
us to evaluate whether patients were able to 
perform their activities of daily living, such as 
walking, as well as aiding us in identifying the 
factors involved in the changes in the functional 
capacity of patients with advanced NSCLC who 
received chemotherapy.
The prognostic value of the 6MWT in patients 
with NSCLC has been investigated, and the results 
have shown that the 6MWD decreases after the 
second cycle of chemotherapy and that a 6MWD 
≥ 400 m can be a positive prognostic factor for 
these patients.(27) A recent study investigating 
patients with NSCLC who were evaluated before 
and one month after chemotherapy reported that 
there was no significant reduction in the 6MWD 
after the treatment,(26) a finding that was similar 
to those of the present study, in which there was 
no reduction in the 6MWD after chemotherapy 
or at six months after the start of treatment.
We conclude that chemotherapy did not 
reduce the body mass or submaximal exercise 
capacity of patients with advanced NSCLC. 
Chemotherapy was beneficial for the PS, and 
this was principally due to the increase in the 
number of asymptomatic patients after the 
six-month follow-up. New studies, involving 
larger samples, are needed in order to confirm 
these findings.
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